-
D-Lin-MC3-DMA: Reliable LNP Assay Design
2026-09-16
A practical, evidence-based guide to using D-Lin-MC3-DMA (SKU A8791) in lipid nanoparticle workflows for cell viability, cytotoxicity, siRNA, and mRNA studies. It connects formulation chemistry, assay controls, handling, data interpretation, and vendor-selection criteria with published performance data.
-
Biomimetic mRNA Nanovaccines Target Neutrophils
2026-09-15
The reference study develops a CD300LD-directed biomimetic mRNA nanovaccine that delivers albumin-fused IL-36γ to tumor-associated neutrophils in hepatocellular carcinoma. By activating rather than depleting these plastic myeloid cells, the platform enhanced antitumor immunity and increased survival in preclinical mouse models, while also highlighting practical requirements for neutrophil-focused validation.
-
CXCR4–EGFR Heteromers Rewire Cancer Signaling
2026-09-15
Comez et al. show that CXCR4 and EGFR can assemble into ligand-responsive oligomeric complexes that couple to PLCγ, Gi proteins, and β-arrestin-2. By combining NanoBRET with nanobody-based proximity ligation in engineered and native cells, the study provides a framework for understanding how receptor co-expression may reshape signaling in cancer.
-
γH2AX DNA Damage Detection Kit Workflow
2026-09-14
Turn γ-H2AX foci into a practical readout for DNA double-strand break detection, repair kinetics, genotoxicity assessment, and radiosensitizer screening. This workflow combines assay setup, quantitative imaging, and troubleshooting guidance for cell-based and tissue studies.
-
BMAL1 Phosphorylation: A Translational Playbook
2026-09-14
BMAL1 phase separation links phosphorylation to circadian transcriptional control. This thought-leadership guide shows how Lambda Protein Phosphatase (RNase-free) can help translational researchers test phosphorylation-dependent mechanisms, validate antibody signals, and build more rigorous workflows around circadian protein biology.
-
Gut-to-Brain α-Synuclein Transfer via the Vagus
2026-09-13
This preprint provides evidence that intestinal mucosal cells can generate or contain fibril-templating α-synuclein activity and transfer it toward the vagus nerve and dorsal motor nucleus. Its combination of intestinal organoids, epithelial-restricted transgenic mice, seeded aggregation assays, and vagotomy offers a framework for testing gut-origin models of Parkinson’s disease while leaving important questions about human disease progression unresolved.
-
HyperScript III RT SuperMix for CRC Profiling
2026-09-12
HyperScript III RT SuperMix supports rigorous CRC biomarker validation from low-input or high-GC RNA. This article connects bile acid metabolism subtyping with contamination-controlled, reproducible qPCR assay design.
-
Triazole ALDH2 Activators for Myocardial Ischemia
2026-09-12
This 2025 ACS Medicinal Chemistry Letters study used molecular simulation and structure optimization to discover triazole-based ALDH2 activators with improved activity and water solubility. Representative compound Z17 produced strong ALDH2 activation and reduced cardiac injury in a mouse ischemia-reperfusion model, supporting ALDH2 as a therapeutic strategy for myocardial infarction.
-
Iptacopan (LNP023): Precision in Complement Research
2026-09-11
A translational perspective on how Iptacopan (LNP023) converts factor B biology into selective alternative-pathway control, with practical guidance for complement assays, animal models, and clinical interpretation.
-
XYD113: Selective GSPT1 Degradation in MYC-Driven Cancer
2026-09-11
The 2026 Acta Pharmacologica Sinica study identifies XYD113 as a CRBN-dependent molecular glue degrader that selectively eliminates GSPT1, a translation termination factor implicated in MYC-driven malignancies. Its cellular potency, substrate selectivity, microsomal stability, and oral xenograft activity support further preclinical development while leaving important questions about exposure, resistance, and clinical translation.
-
YM 58483 (BTP2) SOCE Blocker Guide
2026-09-10
This scenario-based guide explains how YM 58483 (BTP2), a store-operated Ca2+ entry (SOCE) blocker, can clarify calcium-dependent effects in viability, proliferation, cytotoxicity, T-cell, and fibrosis experiments. It provides practical handling guidance for SKU B7542, including solvent controls, concentration planning, interpretation, and vendor selection.
-
Paroxetine Mesylate: An Assay-First Guide
2026-09-10
Paroxetine Mesylate is more than a selective serotonin reuptake inhibitor: it is a useful model for connecting transporter pharmacology with kinase-centered cancer assays. This guide translates the MET/ERBB3 colorectal cancer evidence into practical, decision-oriented research workflows while defining its translational limits.
-
AP20187: A Precision Control Layer for Translation
2026-09-09
AP20187 is more than a chemical inducer of dimerization: it is a controllable experimental layer for testing how engineered protein interactions translate into cellular, metabolic, and cell-therapy outcomes. This thought-leadership analysis connects AP20187 mechanism with 14-3-3 signaling research while defining practical boundaries for translational development.
-
Pollen Spectral Interference in Bioaerosol Classification
2026-09-09
Zhang and colleagues developed a fluorescence-spectrum processing and random-forest workflow to reduce pollen interference during hazardous bioaerosol classification. Fast Fourier transform processing improved reported classification performance to 89.24%, while enabling clearer discrimination of bacterial and toxin-related samples.
-
Reversine and Phenotypic Assay Design
2026-09-08
Reversine is an Aurora kinase inhibitor that links mitotic perturbation to measurable cell-state phenotypes. This article shows how its multi-kinase profile can be evaluated alongside indexed, single-structure assays for sharper cancer and developmental research decisions.